# Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

> **NCT00065442** · PHASE3 · COMPLETED · sponsor: **Dendreon** · enrollment: 512 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Sipuleucel-T
- **BIOLOGICAL:** APC-Placebo

## Key facts

- **NCT ID:** NCT00065442
- **Lead sponsor:** Dendreon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 512 (ACTUAL)
- **Last updated:** 2010-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00065442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00065442, "Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00065442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*